On July 28, 2021, EV Biologics Corp. (OTC PINK:YECO) announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master cell bank. These cells will also be used in optimization of the process for production of therapeutically active, native, extracellular vesicles (EVs) and extracellular particles (EVPs). Lonza Cell Bio Services is a leading provider of cell banks and custom cell isolation services. EV Biologics CEO, Daniel Mckinney said “Leveraging Lonza’s infrastructure for this important step in our first novel cell line generation will establish a solid foundation for further development of cutting-edge native and engineered EVP therapeutics. Our innovative technological approach will be implemented for the first time within the rigorous framework of Lonza’s cell isolation and tissue-processing facilities to accelerate our cGMP process development for novel cell line generation and standardization of EVP-based therapeutics production.”